


EUDRATEC® ADD

ALCOHOL RESISTANCE FOR DELAYED AND EXTENDED DRUG RELEASE FORMULATIONS



EUDRATEC® ADD offers a toolbox for your alcohol resistant formulation and covers all types of modified-release profiles, such as delayed or extended release. Avoiding alcohol-induced dose dumping (ADD) is particularly necessary for drugs like opioids to prevent severe side effects.


We are not only supporting our customer in developing alcohol resistant drug products by developing formulations or controlling substance license handling, Evonik also supports you when it comes to complying with strict regulatory requirements for FDA and EMA approvals.



WHAT MAKES EUDRATEC® ADD UNIQUE?

- EUDRATEC® ADD can covers all types of modified release profiles
- Formulated with conventional equipment and proofed pharmaceutical excipients
- Granted patent family


Case Study EUDRATEC® ADD Delayed Release



Caffeine pellets coated with sodium alginate and EUDRAGIT® L 30 D-55

- Initial non-alcoholic media
- Initial 40%v/v alcoholic media
- 6 months - 40°C/75%r.H. non-alcoholic media
- 6 months - 40°C/75%r.H. 40%v/v alcoholic media

Case Study EUDRATEC® ADD Extended Release



Metoprolol succinate pellets coated with sodium alginate and EUDRAGIT® NE 30 D

- Initial non-alcoholic media
- Initial 40%v/v alcoholic media
- 6 months - 40°C/75%r.H. non-alcoholic media
- 6 months - 40°C/75%r.H. 40%v/v alcoholic media

PATENT NO (WO, EP, US)	TITLE
WO2015121189	Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
WO2016083278	Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
WO2014032742 EP2887926 B1 US20150190348	Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
WO ₂ 014032741 EP2887925A1 US20150209298	Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
WO2012171884 EP2720683 B1 US20140141092	Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
WO2012022498 EP2605759 A1 US20120093926	Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid
WO2010105673	Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
WO2010105672 EP2408436A1 US20120045506	Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
WO ₂ 010034344 EP2326313 B1 US20110229562	PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
WO2010034342 EP2341899 B1 US20110217383	PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
WO2009036812 EP2187876 B1 US20100226978	pH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
WO2009036811 EP2187875 B1 US20100221324	pH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol

This information and all further technical advice are based on our present knowledge and experience. However, it implies no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments. The customer is not released from the obligation to conduct careful inspection and testing of incoming goods. Performance of the product described herein should be verified by testing, which should be carried out only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is neither a recommendation, nor does it imply that similar products could not be used.
 EUDRAGIT® - reg. trademark of Evonik Industries AG and its subsidiaries
 EUDRATEC® - reg. trademark of Evonik Industries AG and its subsidiaries

Evonik Nutrition & Care GmbH
 Health Care Business Line
 Pharma Polymers & Services

healthcare@evonik.com
www.evonik.com/oraldrugdelivery